HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacogenetics of disease-modifying anti-rheumatic drugs.

Abstract
The outcome of treatment with disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients is considerably variable and is also unpredictable. It would be useful clinically if physicians were able to predict responses to DMARDs prior to their administration. One possible cause of differences in efficacy and adverse drug reactions is genetic variation in how individuals metabolize drugs. Based on pharmacogenetics, tailor-made drug therapy, also called personalized drug therapy or individual drug therapy, will be possible with analysis of genetic polymorphism, such as single nucleotide polymorphism (SNP), and analysis of haplotype and diplotype configuration. Several studies of the correlation between the genetic polymorphism of enzymes metabolizing several DMARDs and efficacy or adverse drug reactions have already been reported, suggesting that pharmacogenetics will be applicable to the treatment of RA in the near future.
AuthorsE Tanaka, A Taniguchi, W Urano, H Yamanaka, N Kamatani
JournalBest practice & research. Clinical rheumatology (Best Pract Res Clin Rheumatol) Vol. 18 Issue 2 Pg. 233-47 (Apr 2004) ISSN: 1521-6942 [Print] Netherlands
PMID15121042 (Publication Type: Journal Article, Review)
Chemical References
  • Antirheumatic Agents
Topics
  • Antirheumatic Agents (pharmacokinetics, therapeutic use)
  • Arthritis, Rheumatoid (drug therapy, genetics, metabolism)
  • Genetic Variation
  • Humans
  • Pharmacogenetics

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: